Our malaria vaccine candidate VLPM01 clinical trial designed to evaluate the safety, tolerability, immunogenicity and experimental efficacy of VLPM01 in healthy, malaria-naïve adult volunteers.
The study will have four (4) phases: Screening, Dose Escalation, Controlled Human Malaria Infection (CHMI) and Follow-Up. The study will be conducted at the Walter Reed Army Institute of Research in Silver Spring, Maryland (WRAIR), as this institute has extensive experience in conducting clinical studies of malaria vaccines with CHMI. A total of 36 participants will be enrolled in this study. Thirty (30) eligible participants will participate in the Dose Escalation Phase as vaccinees and 6 eligible participants will be added during the CHMI Phase to act as infectivity controls.
Contact the WRAIR Clinical Trials Center Recruitment Office Phone: 1-866-4-CTC-STUDY (866-428-2788).
VLP Therapeutics Receives FDA Clearance of Investigational New Drug Application and Initiates First Clinical Trial of VLPM01 Malaria Vaccine
Gaithersburg, MD – VLP Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application for a clinical trial of the Company’s VLPM01 malaria vaccine. The Phase
VLP Therapeutics Awarded $3.9 million Grant by Global Health Innovative Technology Fund for Further Development of Dengue Vaccine
December 12, 2018 Gaithersburg, MD - The Global Health Innovative Technology (GHIT) Fund has awarded VLP Therapeutics a $3.9 million grant to further develop a novel tetravalent dengue virus-like particle vaccine. “The GHIT Fund’s commitment
November 29, 2018 Dr. Wataru Akahata, CEO and Founder of VLP Therapeutics was Selected by the Government of Japan as a 2018 Researcher of Significant Contribution to Science Japan’s National Institute of Science and Technology
October 18, 2018 Gaithersburg, MD -- VLP Therapeutics announced the issuance of US Patent 10,098,943 titled, “Flavivirus virus-like particle” on October 16, 2018. This patent supports VLP Therapeutics’ Native Virus Modification virus-like particle platform on
Vaccines are one of the most important inventions in the past centuries. The successful vaccines save millions of lives by eradicating the epidemic and pandemic diseases. I left the research field and formed VLP Therapeutics because I am committed to developing the next generation vaccine technology to treat the diseases that currently lack effective treatment. We believe that our i-αVLP vaccine technology has a potential to create a breakthrough treatments and make significant contributions to the improvement of global public health.